someone explain state board to me like I have not read a paper in years
Asking properly rather than in a comment on somebody else’s thread: someone explain state board to me like I have not read a paper in years.
Asked for the beyond-use date basis and got a real answer with a stability reference attached. Not universal, apparently.
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
ask what the beyond-use date is based on
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
I would not read the price difference as a quality signal.
Agreed — and the follow-up question is what the beyond-use date is based on.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
That figure is the starting material purity, not the finished preparation potency. Two different tests.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
potency testing on the finished preparation is the thing to ask for
the API source is the question nobody asks and everybody should
the pharmacy and the prescriber are two separate questions
The intake asked me three questions and none of them were about my history. That told me everything I needed to know about the model.
salt forms are the recurring argument and the answer is boring
shortage status changes and the whole arrangement changes with it
Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Compounded preparations are not approved products and carry no bioequivalence claim.
This is the distinction the whole board runs on. Everything else follows from it.
a 503B has to register and report, so there is a paper trail to ask for
the shortage list is the whole legal hinge and people skip it
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
do not assume the concentration matches the branded product
- 1shortage status changes and the whole arrangement changes with it7 comments in this branch · started by u/vikram_mbeki
- 2I would not read the price difference as a quality signal. Most of it is the…6 comments in this branch · started by u/medutest_mel